Japanese government bond yields have hit a 30‑year high, putting pressure on risk assets while pushing investors to look harder for growth themes with clear, real world use cases. Healthcare powered by artificial intelligence in Japan sits at the intersection of those needs and opportunities. This article introduces three AI focused healthcare stocks from our screener that investors may wish to evaluate as they consider that shift.
The three stocks highlighted below are only a small sample of the AI healthcare theme, with our full screen surfacing 7 more companies that carry similarly compelling stories that are not covered here. To see the broader field and identify which tickers best fit your own risk and return preferences, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener
Chugai Pharmaceutical is a long established biopharma group focused on oncology and immunology treatments, now weaving agentic AI directly into its drug discovery process to search for new therapies faster and at scale.
Chugai Pharmaceutical generates all of its ¥1,342.8b pharmaceuticals revenue from its core drug portfolio, backed by a market value of about ¥10.9t that reflects its role within Roche and its push into AI enabled research.
“Phylo and Chugai Pharmaceutical entered a collaboration to use Phylo’s Biomni Lab AI platform across Chugai’s drug discovery workflows, covering areas such as single cell analysis, human genetics, disease biology, and target evaluation.”
What this AI push ultimately means for Chugai Pharmaceutical’s margins and long term earnings power hinges on how one execution risk plays out.
That execution risk is exactly what the full narrative for Chugai Pharmaceutical unpacks in detail, showing where AI could accelerate returns and where legacy drug development may still be dragging.
Wellness Communications runs AI enabled health data platforms in Japan, led by the Growbase cloud system for centralized health records and the SUZAKU AI HR tool for workforce health analytics. Most of its ¥13,018 million revenue comes from Health Check Solutions, with ¥1,524 million from Health Management Cloud and ¥236 million from Medical Institution Support, and the stock is valued at about ¥14.9 billion.
Wellness Communications ties directly into AI powered healthcare through Growbase and SUZAKU, with earnings forecast to rise 25.85% annually and recent revenue growth of 13% as hospitals and employers lean on better data and staff health insights. One potential funding pressure, however, could meaningfully affect how much of that potential reaches margins.
